Leqembi subcutaneous data shows similar efficacy to IV in Alzheimer's
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference�
July 12, 2026 11:15 AM EDTNew clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners
TOKYO and CAMBRIDGE, Mass., July 12, 2026 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer's Association... More
